Analytical Data
-
Gene name
CTGF
- Application
-
Alternative Names
CCN2; HCS24; IGFBP8; NOV2; Insulin-Like Growth Factor-Binding Protein 8; Hypertrophic Chondrocyte-Specific Protein 24; CCN Family Member 2
-
Species
Rat
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9R1E9
-
Expression Region
Gln25~Ala347
-
Molecular Weight
68kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Connective Tissue Growth Factor (CTGF), also known as CCN2, is a multifaceted protein that plays a pivotal role in various physiological and pathological processes, including fibrosis, wound healing, and tissue repair. Initially identified as a secreted factor associated with cell proliferation and extracellular matrix formation, CTGF is of particular interest in the context of fibrotic diseases and inflammatory responses due to its ability to regulate cellular functions and promote collagen synthesis. Research has shown that abnormal CTGF expression is implicated in disorders such as systemic sclerosis, kidney fibrosis, and chronic liver diseases. The exploration of CTGF as a therapeutic target has gained momentum, with recombinant CTGF protein being studied for its potential to modulate fibrotic pathways. Various experimental models have demonstrated the protein's effects on cellular migration, proliferation, and ECM remodeling, making it a crucial player in tissue homeostasis. Furthermore, the development of CTGF inhibitors and their therapeutic applications in fibrotic conditions highlight the urgency in understanding its molecular mechanisms. This growing body of research positions CTGF not only as a vital biomarker for fibrotic diseases but also as a promising candidate for novel therapeutic strategies aimed at mitigating fibrosis and enhancing tissue regeneration. However, further studies are required to elucidate the detailed signaling pathways and interactions involving CTGF, ultimately paving the way for clinical applications that harness its properties in regenerative medicine and fibrotic disease management.
